Biologic Videos

  1. August BioServices Capabilities Update April 2026: Fill/Finish 4/28/2026

    A U.S.-based sterile injectable CDMO delivering scalable small and large molecule manufacturing, supported by advanced aseptic technologies, integrated quality systems, and commercial-ready capabilities.

  2. From DNA To IND In As Little As 6 Months 4/27/2026

    Discover how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment.

  3. Biologics Tech Transfer & Validation at Scale: A Better Path to GMP 4/24/2026

    Explore where tech transfer and validation commonly falter, and how disciplined execution helps teams maintain control through PPQ and beyond.

  4. West Vantage™ Goes Beyond Contract Manufacturing 4/23/2026

    Successfully advancing a drug-delivery device to market demands more than technical expertise; it requires coordinated execution, regulatory insight, and the ability to scale without disruption.

  5. One Program, Many CDMOs: Managing Multi-Partner Strategies 4/22/2026

    As development and manufacturing science for new drugs and therapies grow more complex and compressed for time, biotechs and pharma organizations are often forced to separate work across multiple CDMOs and diverse locations, for example drug substance in Asia and drug product in the U.S.

  6. Unlocking The Next Wave Of Cancer Vaccines 4/21/2026

    Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.

  7. Syringe–Cartridge Filling Line In Action 4/21/2026

    Designed for medium‑ to high‑volume ISO syringes and cartridges, this high‑speed filling line delivers tight manufacturing control, supports larger batches, and meets growing biologics demand.

  8. Quality By Design For Outsourced Operations 4/16/2026

    A practical guide to applying Quality by Design to outsourced GXP operations, helping virtual and hybrid sponsors maintain regulatory control, inspection readiness, and accountability.

  9. The Biosimilar Market Reality: Expansion, Risk, And Consolidation 4/16/2026

    An executive view on how biosimilar misconceptions around demand, risk, and cost drove market crowding, manufacturing pressure, and eventual consolidation across the industry.

  10. Less Risk, More Speed -The New Blueprint For Bioconjugate Development 4/15/2026

    A fireside chat on how integrated development models reduce risk and accelerate bioconjugate timelines from discovery through GMP manufacturing.